share_log

PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer

pmvファーマシューティカルズのリザタポプトの上位卵巣癌におけるPYNNACLE第I相試験データが、2024年SGO婦人科がん年次会議で口頭発表で注目セクターに掲載されました。

Benzinga ·  03/18 16:02
  • Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting
  • Of the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response with a seven-month median duration of response and a favorable safety profile
    • Rezatapopt is a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type which is being evaluated in a registrational Phase 2 study
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする